Monitor CMS's final determination in November on EsoGuard's gapfill payment basis and the effective date of the new Category III CPT code. The start of Medicare claims submission at the Texas laboratory this month is a near-term catalyst for revenue recognition, but the filing provides no revenue or volume data to size the opportunity.
Price Chart
Executive Summary
Lucid Diagnostics announced three regulatory advances for its EsoGuard test and EsoCheck device: a CMS advisory panel recommended maintaining EsoGuard's gapfill payment basis under the CLFS; the AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection with EsoCheck; and a proposed ICD-10-CM diagnosis code for positive EsoGuard results received a favorable response from the CDC/NCHS committee. The company will begin submitting Medicare claims this month for its Texas laboratory under EsoGuard's PLA code 0114U. These are positive but non-financial milestones that improve the reimbursement and coding infrastructure, with no revenue or earnings data provided.
Key Facts
- CMS advisory panel recommended maintaining EsoGuard's original gapfill payment basis under the CLFS; final determinations expected in November.
- AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic esophageal cell collection performed with EsoCheck.
- CDC/NCHS committee positively received a proposed ICD-10-CM diagnosis code (R85.83) for positive EsoGuard results; finalization expected after public comment.
- Lucid will begin submitting Medicare claims this month under PLA code 0114U for tests at its Texas laboratory.
- California laboratory Medicare claims will begin once a final revised Local Coverage Determination is effective.
- Lucid owns and operates two CLIA-certified laboratories in Lake Forest, CA and Irving, TX.
Financial Impact
No financial figures provided; the filing describes regulatory and coding advances that could expand Medicare reimbursement access but does not quantify revenue or payment rates.
Risk Factors
- CMS final determination in November could deviate from the advisory panel's recommendation.
- Medicare claims submission at the Texas laboratory may face administrative or coverage delays.
- No revenue, volume, or pricing data provided — commercial impact is uncertain.
- California laboratory claims remain contingent on a pending Local Coverage Determination revision.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043659 |
| Exhibit: ex99-1.htm | 0001493152-26-043659 |
| Document: 0001493152-26-043659-index-headers.html | 0001493152-26-043659 |
| Document: 0001493152-26-043659-index.html | 0001493152-26-043659 |
| Document: 0001493152-26-043659.txt | 0001493152-26-043659 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.4110 $0.5007 | ▼ −21.82% | ▼ −21.11% | $0.4380 (−6.57%) |
Oct 16, 2026 11d ago | 8-K | $0.3770 $0.3520 | ▲ +6.63% | ▲ +6.97% | $0.4380 (−16.18%) |
Sep 22, 2026 5w ago | 8-K | $0.8930 $0.8390 | ▼ −6.05% | ▼ −5.33% | $0.4380 (−50.95%) |
Aug 13, 2026 10w ago | 8-K | $0.9649 $0.9677 | ▲ +0.29% | ▲ +0.49% | $0.4380 (−54.61%) |
May 14, 2026 23w ago | 8-K | $1.02 $0.9910 | ▲ +2.84% | ▲ +1.62% | $0.4380 (+57.06%) |
Apr 24, 2026 26w ago | 8-K | $1.06 $1.04 | ▼ −1.89% | ▼ −1.40% | $0.4380 (−58.68%) |
Apr 23, 2026 26w ago | 8-K | $1.07 $1.06 | ▼ −0.93% | ▼ −1.10% | $0.4380 (−59.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers